UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.947

Sortiert nach

Long‐term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy

Alimentary pharmacology & therapeutics, 2018-07, Vol.48 (1), p.65-77

2018

Link zum Volltext

Verfügbarkeit prüfen

Randomised clinical trial: a placebo‐controlled study of intravenous golimumab induction therapy for ulcerative colitis

Alimentary pharmacology & therapeutics, 2015-09, Vol.42 (5), p.504-514

2015

Link zum Volltext

Verfügbarkeit prüfen

Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD‐subgroup analyses across four randomized trials

Alimentary pharmacology & therapeutics, 2009-08, Vol.30 (3), p.210-226

2009

Link zum Volltext

Verfügbarkeit prüfen

Do Stronger Wise‐Thinking Dispositions Facilitate Auditors' Objective Evaluation of Evidence When Assessing and Addressing Fraud Risk?

Contemporary accounting research, 2021-09, Vol.38 (3), p.1679-1711

2021

Link zum Volltext

Verfügbarkeit prüfen

Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis

Gastroenterology (New York, N.Y. 1943), 2014, Vol.146 (1), p.85-95

2014

Link zum Volltext

Verfügbarkeit prüfen

943d A Phase 2/3 Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Subcutaneous Golimumab Induction Therapy in Patients with Moderately to Severely Active Ulcerative Colitis: PURSUIT SC

Gastroenterology (New York, N.Y. 1943), 2012-05, Vol.142 (5), p.S-161-S-161

2012

Link zum Volltext

Verfügbarkeit prüfen

A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease

Gastroenterology (New York, N.Y. 1943), 2008-10, Vol.135 (4), p.1130-1141

2008

Link zum Volltext

Verfügbarkeit prüfen

Predictive value of patient-reported outcomes to mucosal healing in patients with moderately to severely active ulcerative colitis

Value in health, 2014-05, Vol.17 (3), p.A40-A40

2014

Link zum Volltext

Verfügbarkeit prüfen

Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis

The New England journal of medicine, 2005-12, Vol.353 (23), p.2462-2476

2005

Link zum Volltext

Verfügbarkeit prüfen

Pasteurization of Discard Mycoplasma Mastitic Milk Used to Feed Calves: Thermal Effects on Various Mycoplasma

Journal of dairy science, 2000-10, Vol.83 (10), p.2285-2288

2000

Link zum Volltext

Verfügbarkeit prüfen

Evolution of sporadic olivopontocerebellar atrophy into multiple system atrophy

Neurology, 2000-08, Vol.55 (4), p.527

2000

Link zum Volltext

Verfügbarkeit prüfen

Patterns of neuropsychological performance in multiple system atrophy compared to sporadic and hereditary olivopontocerebellar atrophy

Brain and cognition, 2002-11, Vol.50 (2), p.194-206

2002

Link zum Volltext

Verfügbarkeit prüfen

Risk for perioperative myocardial infarction and mortality in patients undergoing hip or knee arthroplasty: the role of anemia

Transfusion (Philadelphia, Pa.), 2011-01, Vol.51 (1), p.82-91

2011

Link zum Volltext

Verfügbarkeit prüfen

New Trends in Databases and Information Systems: ADBIS 2019 Short Papers, Workshops BBIGAP, QAUCA, SemBDM, SIMPDA, M2P, MADEISD, and Doctoral Consortium, Bled, Slovenia, September 8-11, 2019, Proceedings

1st ed. 2019., 2019

Link zum Volltext

Verfügbarkeit prüfen

Advances in Databases and Information Systems: 23rd European Conference, ADBIS 2019, Bled, Slovenia, September 8-11, 2019, Proceedings

1st Edition 2019, 2019

Link zum Volltext

Verfügbarkeit prüfen

Broadband Networks, Smart Grids and Climate Change

1. Aufl., 2013

Link zum Volltext

Verfügbarkeit prüfen

PET measures of benzodiazepine receptors in progressive supranuclear palsy

Neurology, 2000-05, Vol.54 (9), p.1768

2000

Link zum Volltext

Verfügbarkeit prüfen

OP36 Efficacy and safety of combination induction therapy with guselkumab and golimumab in participants with moderately-to-severely active Ulcerative Colitis: Results through week 12 of a phase 2a randomized, double-blind, active-controlled, parallel-group, multicenter, proof-of-concept study

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i042-i043

2022

Link zum Volltext

Verfügbarkeit prüfen

P477 Clinical remission by legacy vs. FDA definitions: definition justification and results from UNIFI Study

Journal of Crohn's and colitis, 2019-01, Vol.13 (Supplement_1), p.S350-S351

2019

Link zum Volltext

Verfügbarkeit prüfen

OP23 The efficacy and safety of guselkumab induction therapy in patients with moderately to severely active Ulcerative Colitis: Phase 2b QUASAR Study results through week 12

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i025-i026

2022

Link zum Volltext

Verfügbarkeit prüfen

A141 DIFFERENT INDUCTION RESPONSE CRITERIA DO NOT INFLUENCE 1 YEAR RESPONSE AND REMISSION RATES OF USTEKINUMAB 90MG Q8W IN PHASE III PROGRAM

Journal of the Canadian Association of Gastroenterology, 2018-03, Vol.1 (suppl_1), p.242-243

2018

Link zum Volltext

Verfügbarkeit prüfen

Cognitive, behavioral, and motor effects of the NMDA antagonist ketamine in Huntington's disease

Neurology, 1997-07, Vol.49 (1), p.153

1997

Link zum Volltext

Verfügbarkeit prüfen

Advanced information systems engineering workshops: 28th International Conference, CAiSE 2016, Ljubljana, Slovenia, June 13-17, 2016. Proceedings

1st ed. 2016, 2016

Link zum Volltext

Verfügbarkeit prüfen

DOP56 Ustekinumab maintained clinically meaningful improvement in health-related quality of life in patients with moderate to severe ulcerative colitis: Results from the UNIFI long-term extension

Journal of Crohn's and colitis, 2020-01, Vol.14 (Supplement_1), p.S094-S095

2020

Link zum Volltext

Verfügbarkeit prüfen

DOP12 Efficacy of ustekinumab for ulcerative colitis through 2 years: Results of the UNIFI maintenance study and long-term extension

Journal of Crohn's and colitis, 2020-01, Vol.14 (Supplement_1), p.S049-S049

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 1.947

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(952)
Mit Volltextzugriff
(1.861)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(935)
Technology
(698)
Computer Science
(694)
Computer Science, Theory & Methods
(633)
Computer Science, Information Systems
(468)
Computer Science, Software Engineering
(240)
Computer Science, Artificial Intelligence
(226)
Life Sciences & Biomedicine
(205)
Humans
(176)
Computer Science, Interdisciplinary Applications
(154)
Telecommunications
(114)
Exact Sciences And Technology
(99)
Applied Sciences
(98)
Computer Science; Control Theory; Systems
(96)
Male
(93)
Female
(92)
Software
(91)
Physical Sciences
(82)
Middle Aged
(69)
Adult
(55)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Long‐term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy

Randomised clinical trial: a placebo‐controlled study of intravenous golimumab induction therapy for ulcerative colitis

Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD‐subgroup analyses across four randomized trials

Do Stronger Wise‐Thinking Dispositions Facilitate Auditors' Objective Evaluation of Evidence When Assessing and Addressing Fraud Risk?

Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis

943d A Phase 2/3 Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Subcutaneous Golimumab Induction Therapy in Patients with Moderately to Severely Active Ulcerative Colitis: PURSUIT SC

A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease

Predictive value of patient-reported outcomes to mucosal healing in patients with moderately to severely active ulcerative colitis

Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis

Pasteurization of Discard Mycoplasma Mastitic Milk Used to Feed Calves: Thermal Effects on Various Mycoplasma

Evolution of sporadic olivopontocerebellar atrophy into multiple system atrophy

Patterns of neuropsychological performance in multiple system atrophy compared to sporadic and hereditary olivopontocerebellar atrophy

Risk for perioperative myocardial infarction and mortality in patients undergoing hip or knee arthroplasty: the role of anemia

New Trends in Databases and Information Systems: ADBIS 2019 Short Papers, Workshops BBIGAP, QAUCA, SemBDM, SIMPDA, M2P, MADEISD, and Doctoral Consortium, Bled, Slovenia, September 8-11, 2019, Proceedings

Advances in Databases and Information Systems: 23rd European Conference, ADBIS 2019, Bled, Slovenia, September 8-11, 2019, Proceedings

Broadband Networks, Smart Grids and Climate Change

PET measures of benzodiazepine receptors in progressive supranuclear palsy

OP36 Efficacy and safety of combination induction therapy with guselkumab and golimumab in participants with moderately-to-severely active Ulcerative Colitis: Results through week 12 of a phase 2a randomized, double-blind, active-controlled, parallel-group, multicenter, proof-of-concept study

P477 Clinical remission by legacy vs. FDA definitions: definition justification and results from UNIFI Study

OP23 The efficacy and safety of guselkumab induction therapy in patients with moderately to severely active Ulcerative Colitis: Phase 2b QUASAR Study results through week 12

A141 DIFFERENT INDUCTION RESPONSE CRITERIA DO NOT INFLUENCE 1 YEAR RESPONSE AND REMISSION RATES OF USTEKINUMAB 90MG Q8W IN PHASE III PROGRAM

Cognitive, behavioral, and motor effects of the NMDA antagonist ketamine in Huntington's disease

Advanced information systems engineering workshops: 28th International Conference, CAiSE 2016, Ljubljana, Slovenia, June 13-17, 2016. Proceedings

DOP56 Ustekinumab maintained clinically meaningful improvement in health-related quality of life in patients with moderate to severe ulcerative colitis: Results from the UNIFI long-term extension

DOP12 Efficacy of ustekinumab for ulcerative colitis through 2 years: Results of the UNIFI maintenance study and long-term extension

Suchergebnisse filtern